1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

US FDA's Complex Trial Design Pilot Might Be Handicapped By Disclosure Requirements

 
• By Derrick Gingery

FDA wants to publicize some aspects of designs accepted into pilot, which might discourage industry participation.  

Abstract mash line and point magnifying glass on white background with an inscription. Starry sky or space, consisting of stars and the universe. Vector business illustration

When it comes to the US FDA's complex innovative trial design pilot, it's unclear which will be more intricate: the new development pathways formed through the program, or the negotiations with the agency before a sponsor can even join.

FDA will require details of the trials used in the program to be released for the benefit of the drug industry at large

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 
• By Sarah Karlin-Smith

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.

Biomarker Negativity At Issue In Pfizer Bid To Broaden Talzenna CRPC Claim

 
• By Bridget Silverman

The FDA questioned Pfizer’s reliance on a “large, incompletely defined” subgroup of castration-resistant prostate cancer patients without known HRR gene alterations in its review of the proposed expansion of Talzenna’s first-line indication for HRR-mutated CRPC to an all-comers population.